Keller Rohrback L.L.P. Investigates Abbott Laboratories Regarding Weight-Loss Drug Meridia

SEATTLE--(BUSINESS WIRE)-- Attorney Advertising. Keller Rohrback L.L.P. (www.krclassaction.com) announces that it is continuing its investigation of the side effects associated with the use of Meridia, a prescription weight-loss drug. Meridia, which contains the appetite suppressant sibutramine, is manufactured and marketed by Abbott Laboratories (NYSE: ABT). Recently, Abbott agreed to withdraw Meridia from the market in response to a request from the Food and Drug Administration (“FDA”). The FDA submitted its request after reviewing data from the Sibutramine Cardiovascular Outcomes Trial (SCOUT).

According to a recent study published in the New England Journal of Medicine, people with a history of heart disease that take Meridia may be at an increased risk for a heart attack or a stroke. The study also confirmed concerns that had been previously raised about the safety of the use of Meridia by people with other heart problems.

If you or someone you know was injured as a result of taking Meridia, or you would like more information regarding this investigation, please contact attorney Michael Woerner at (800) 776-6044 or via email at [email protected]rrohrback.com.

Keller Rohrback, with offices in Seattle, Phoenix, and New York, has extensive experience with pharmaceutical litigation, including cases involving the diet drugs Fen-Phen and Redux, as well as Propulsid and Vioxx medications. The efforts of the firm’s trial lawyers have resulted in consumers recovering tens of millions of dollars.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.



CONTACT:

Keller Rohrback L.L.P.
Attorney
Michael W. Woerner, 800-776-6044
[email protected]
www.krclassaction.com

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Professional Services  Legal  FDA

MEDIA:

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.